Crossbow - About the company
Crossbow is a series B company based in Cambridge (United States), founded in 2021. It operates as a Developer of antibody therapies for cancer treatment. Crossbow has raised $187M in funding from investors like Pfizer, Taiho Ventures and Arkin. The company has 3315 active competitors, including 1123 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
- Website
- www.crossbowtx.com/
- Email ID
- *****@crossbowtx.com
Key Metrics
Founded Year
2021
Location
Cambridge, United States
Stage
Series B
Total Funding
$187M in 3 rounds
Latest Funding Round
Ranked
356th among 3315 active competitors
Employee Count
10 - 49 as on Mar 01, 2026
Sign up to download Crossbow's company profile
Crossbow's funding and investors
Crossbow has raised a total funding of $187M over 3 rounds. Its first funding round was on Jul 11, 2023. Its latest funding round was a Series B round on Mar 18, 2026 for $*****. 10 investors participated in its latest round. Crossbow has 14 institutional investors.
Here is the list of recent funding rounds of Crossbow:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 18, 2026 | 3053806 | Series B | 4878488 | 9648427 | 5734732 | 5262518 |
Sep 17, 2025 | 9436562 | Series A | 8853080 | 1698040 | 2062355 | 4301675 |
Jul 11, 2023 | 8092813 | Series A | 8036661 | 9230135 |
Access funding benchmarks and valuations. Sign up today!View details of Crossbow's funding rounds and investors
Crossbow's founders and board of directors
Founder? Claim ProfileCrossbow's employee count trend
Crossbow has 10 - 49 employees as of Mar 26. Here is Crossbow's employee count trend over the years:
Uncover Crossbow's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Crossbow's Competitors and alternates
Top competitors of Crossbow include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Crossbow, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
356th |  Crossbow 2021, Cambridge (United States), Series B | Developer of antibody therapies for cancer treatment | $187M | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Crossbow's competitors? Click here to see the top ones
Crossbow's Investments and acquisitions
Crossbow has made no investments or acquisitions yet.
Reports related to Crossbow
Here is the latest report on Crossbow's sector:
News related to Crossbow
Media has covered Crossbow for 1 event in last 1 year.
•
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell EngagersEndpoints•Mar 18, 2026•Crossbow, Arkin, MPM BioImpact, LifeLink Ventures and 11 others
•
•
Pfizer, Lilly back Crossbow Therapeutics, a startup headed byThe Business Journals•Jul 12, 2023•MPM BioImpact, Lilly, Pfizer, Crossbow and 4 others
•
Crossbow Therapeutics Raises $80M in Series A FinancingFinSMEs•Jul 12, 2023•Crossbow, MPM BioImpact, Pfizer, Polaris Partners and 6 others
•
Crossbow raises Series A funds to develop cancer antibodiesPharmaceutical Technology•Jul 12, 2023•Crossbow, Pfizer, Polaris Partners, BVF Partners and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Crossbow
Explore our recently published companies
- Faultless Aesthetics - Clermont based, Unfunded company
- Sosplan Creative - Indonesia based, 2021 founded, Unfunded company
- Sweet Atoms - Brisbane based, 2025 founded, Unfunded company
- Infinitymedicalstore - Jakarta based, Unfunded company
- Silicon Nigeria - Nigeria based, 2024 founded, Unfunded company
- Jian Yuan Tian Hua - Unfunded company
